HER2-Negative Breast Cancer: Epidemiology Forecast to 2034

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed incident cases of all invasive breast cancer and HER2- breast cancer
2.4.4 Forecast assumptions and methods: diagnosed incident cases of invasive HER2- breast cancer by stage at diagnosis
2.4.5 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer
2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer by stage
2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer with progression to metastatic disease
2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status
2.4.9 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer with resectable tumors
2.4.10 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity
2.4.11 Forecast assumptions and methods: five-year diagnosed prevalent cases of invasive HER2- breast cancer by mutations and biomarkers
2.4.12 Forecast assumptions and methods: diagnosed five-year diagnosed prevalent cases of invasive HER2- breast cancer with other HER2 activating mutations
2.5 Epidemiological forecast for invasive HER2- breast cancer (2024-34)
2.5.1 Diagnosed incident cases of all invasive breast cancer
2.5.2 Age-specific diagnosed incident cases of all invasive breast cancer
2.5.3 Diagnosed incident cases of invasive HER2-/HR+ breast cancer
2.5.4 Diagnosed incident cases of invasive HER2-/HR- breast cancer
2.5.5 Diagnosed incident cases of invasive HER2-/HR+ breast cancer and invasive HER2-/HR- breast cancer by stage at diagnosis
2.5.6 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer
2.5.7 Five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer
2.5.8 Five-year diagnosed prevalent cases of invasive HER2- breast cancer by stage
2.5.9 Five-year diagnosed prevalent cases of invasive HER2- breast cancer with progression to metastatic disease
2.5.10 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status
2.5.11 Five-year diagnosed prevalent cases of invasive HER2-/HR+ and HER2-/HR- breast cancer by resectable tumors
2.5.12 Five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity
2.5.13 Five-year diagnosed prevalent cases of invasive HER2- breast cancer by mutations and biomarkers
2.5.14 Five-year diagnosed prevalent cases of invasive HER2- breast cancer with other HER2 activating mutations
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 Limitations of the analysis
2.6.3 Strengths of the analysis

3.1 Bibliography
3.2 Primary research - prescriber survey
3.3 About the authors
3.3.1 Epidemiologist
3.3.2 Reviewers
3.3.3 Vice President of Disease Intelligence and Epidemiology
3.3.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

• Contact the Publisher

Table 1: Summary of newly added data types
Table 2: Summary of updated data types
Table 3: Risk factors and comorbidities for HER2- breast cancer
Table 4: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by mutations and biomarkers, N, women, ages =18 years, 2024
Table 5: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer by mutations and biomarkers, N, women, ages =18 years, 2024
Table 6: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer with other HER2 activating mutations, N, women, ages =18 years, 2024
Table 7: 8MM, five-year prevalent cases of invasive HER2-/HR- breast cancer with other HER2 activating mutations, N, women, ages =18 years, 2024
Table 8: High-prescribing physicians surveyed, by country

Figure 1: 8MM, diagnosed incident cases of invasive HER2- breast cancer, women, N, ages =18 years, 2024 and 2034
Figure 2: 8MM, five-year diagnosed prevalent cases of invasive HER2- breast cancer, women, N, ages =18 years, 2024 and 2034
Figure 3: 8MM, diagnosed incidence of invasive HER2- breast cancer, women, cases per 100,000 population, ages =18 years, 2014-34
Figure 4: 8MM, five-year diagnosed prevalence of invasive HER2- breast cancer, women, %, ages =18 years, 2018-34
Figure 5: 8MM, sources used to forecast the diagnosed incident cases of all invasive breast cancer
Figure 6: 8MM, sources used and not used to forecast the diagnosed incident cases of invasive HER2- breast cancer
Figure 7: 8MM, sources used and not used to forecast the diagnosed incident cases of invasive HER2- breast cancer by stage at diagnosis
Figure 8: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2- breast cancer
Figure 9: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status
Figure 10: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2- breast cancer by resectable tumors
Figure 11: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity
Figure 12: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2- breast cancer by mutations and biomarkers
Figure 13: 8MM, sources used to forecast the five-year diagnosed prevalent cases of invasive HER2- breast cancer with other HER2 activating mutations in the 8MM
Figure 14: 8MM, diagnosed incident cases of all invasive breast cancer, N, women, ages =18 years, 2024
Figure 15: 8MM, diagnosed incident cases of all invasive breast cancer by age, N, women, 2024
Figure 16: 8MM, diagnosed incident cases of invasive HER2-/HR+ breast cancer, N, women, ages =18 years, 2024
Figure 17: 8MM, diagnosed incident cases of invasive HER2-/HR- breast cancer, N, women, ages =18 years, 2024
Figure 18: 8MM, diagnosed incident cases of invasive HER2-/HR+ breast cancer by stage at diagnosis, N, women, ages =18 years, 2024
Figure 19: 8MM, diagnosed incident cases of invasive HER2-/HR- breast cancer by stage at diagnosis, N, women, ages =18 years, 2024
Figure 20: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer, N, women, ages =18 years, 2024
Figure 21: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer, N, women, ages =18 years, 2024
Figure 22: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by stage, N, women, ages =18 years, 2024
Figure 23: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer by stage, N, women, ages =18 years, 2024
Figure 24: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer with progression to metastatic disease, N, women, ages =18 years, 2024
Figure 25: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer with progression to metastatic disease, N, women, ages =18 years, 2024
Figure 26: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by menopausal status, N, women, ages =18 years, 2024
Figure 27: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by resectable tumors, N, women, ages =18 years, 2024
Figure 28: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR- breast cancer by resectable tumors, N, women, ages =18 years, 2024
Figure 29: 8MM, five-year diagnosed prevalent cases of invasive HER2-/HR+ breast cancer by HR positivity, N, women, ages =18 years, 2024